GlassScriptPhysician profile
Panida Piboolnurak
NPI 1609087881
$4,579.84
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,472 · 2020: $259 · 2021: $2,228 · 2022: $620.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,359.91 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $700.00 | 2021 | |
| Boston Scientific Corporation | $535.43 | 2019 | |
| Abbott Laboratories | $322.10 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $234.01 | 2019-2020 | |
| Vertex Pharmaceuticals Incorporated | $225.00 | 2022 | |
| Mdd US Operations, LLC | $219.73 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $217.97 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $210.21 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $153.59 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $117.57 | 2020-2022 | |
| Acorda Therapeutics, INC | $95.13 | 2019 | |
| Lilly USA, LLC | $68.92 | 2019 | |
| Medtronic, INC. | $63.20 | 2022 | |
| Merz North America, INC. | $57.07 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Panida Piboolnurak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.